Scholarlink

<p>HER2-low expression is associated with hormone receptor (HR) expression in HR-positive breast cancer. We aimed to evaluate its association with androgen receptor (AR) among 196 patients with metastatic triple-negative breast cancer (mTNBC). Central determination of AR showed significant enrichment in HER2-low compared with HER2-0 mTNBC (mean: 33.7% vs. 21.4%, <i>p</i> = 0.038), whereas no significant immunological differences were observed. HER2-low/AR-positive patients trended towards longer overall survival, highlighting the potential relevance of these biomarkers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月13日

查看全文
  • Paolo Tarantino,
  • Jaeyoon Cha,
  • Busem Binboga Kurt,
  • Xiangying Chu,
  • Bojana Jovanović,
  • Andrew Zhou,
  • Melissa Hughes,
  • Douglas Russo,
  • Molly DiLullo,
  • Eileen Wrabel,
  • Rinath Jeselsohn,
  • Nancy U. Lin,
  • Jamie Carter,
  • Yisang Serenity Chen,
  • Tianyu Li,
  • Nabihah Tayob,
  • Elizabeth A. Mittendorf,
  • Stuart J. Schnitt,
  • Shom Goel,
  • Sara M. Tolaney

摘要

HER2-low expression is associated with hormone receptor (HR) expression in HR-positive breast cancer. We aimed to evaluate its association with androgen receptor (AR) among 196 patients with metastatic triple-negative breast cancer (mTNBC). Central determination of AR showed significant enrichment in HER2-low compared with HER2-0 mTNBC (mean: 33.7% vs. 21.4%, p = 0.038), whereas no significant immunological differences were observed. HER2-low/AR-positive patients trended towards longer overall survival, highlighting the potential relevance of these biomarkers.